Today’s Jaguar Health Conference Call Moved to 5:45 p.m. Eastern Time

First Post-Merger Earnings Call for Jaguar and its Wholly-Owned
Subsidiary, Napo Pharmaceuticals, Regarding Sales of Napo’s FDA-Approved
Human Drug, Mytesi, an Antidiarrheal Indicated for the Symptomatic
Relief of Noninfectious Diarrhea in Adult Patients with HIV/AIDS on
Antiretroviral Therapy

SAN FRANCISCO–(BUSINESS WIRE)–Jaguar Health, Inc. (NASDAQ: JAGX) (Jaguar), a commercial stage
natural-products pharmaceuticals company focused on developing novel,
sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis, announced that its
conference call originally scheduled for 4:30 p.m. Eastern Time today
has been rescheduled for 5:45pm Eastern Time today. The call is being
hosted to review year-to-date sales figures for Jaguar and Napo
Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar
focused on human health and the ongoing commercialization of, and
development of follow-on indications for, Mytesi®
(crofelemer), Napo’s first-in-class, FDA-approved anti-secretory human
prescription drug.

The merger of Jaguar Animal Health and Napo became effective July 31,
2017. As a result, the quarterly report Jaguar will be filing on
November 14, 2017 on Form 10-Q with the U.S. Securities and Exchange
Commission will only include Mytesi® sales for August and
September of this year. On today’s call, Jaguar’s CEO and members of the
Company’s sales and marketing management team will review Mytesi®-related
commercial activities and results for the period of January to July of
2017, when Napo was still a private company, in addition to discussing
Mytesi® launch activities and sales performance following the
merger, for the period of August through October of 2017, as well as
current and planned commercial activities intended to grow Mytesi®
sales.

The management team will also review development activities focused on
planned follow-on indications for Mytesi®.

Conference Call Dial-In Instructions

Investors interested in listening to the live call should dial
888-394-8218 (Toll Free), 323-701-0225 (International). Please ask the
operator to connect you to the call or provide the conference ID number:
6593876. A live webcast of the conference call will be available online
which can be accessed on the investor relations section of the Jaguar
website (click
here
). Please allow extra time prior to the call to visit the site
and download any necessary software to listen to the live broadcast.

For interested individuals unable to join the conference call, a replay
of the webcast will be available on the investor relations section of
Jaguar’s website (click
here
) for 90 days following the call. Also, a dial-in replay of the
call will be available through November 21, 2017, at 844-512-2921 (U.S.
Toll Free) or 412-317-6671 (International). Participants must use the
following code to access the dial-in replay of the call: 6593876.

About Mytesi®

Mytesi® (crofelemer) is an antidiarrheal indicated for the
symptomatic relief of noninfectious diarrhea in adult patients with
HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not
indicated for the treatment of infectious diarrhea. Rule out infectious
etiologies of diarrhea before starting Mytesi®. If infectious
etiologies are not considered, there is a risk that patients with
infectious etiologies will not receive the appropriate therapy and their
disease may worsen. In clinical studies, the most common adverse
reactions occurring at a rate greater than placebo were upper
respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%),
flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the Amazon rainforest. Napo has
established a sustainable harvesting program for crofelemer to ensure a
high degree of quality and ecological integrity.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage natural-products
pharmaceuticals company focused on developing novel, sustainably derived
gastrointestinal products for both human prescription use and animals on
a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc.,
focuses on developing and commercializing proprietary human
gastrointestinal pharmaceuticals for the global marketplace from plants
used traditionally in rainforest areas. Our Mytesi®
(crofelemer) product is approved by the U.S. FDA for the symptomatic
relief of noninfectious diarrhea in adults with HIV/AIDS on
antiretroviral therapy. Mytesi® is in development for
multiple possible follow-on indications, including cancer
therapy-related diarrhea; orphan-drug indications for infants and
children with congenital diarrheal disorders and short bowel syndrome;
supportive care for inflammatory bowel disease (IBD); irritable bowel
syndrome (IBS); and as a second-generation anti-secretory agent for use
in cholera patients. Canalevia is our lead animal
prescription drug candidate, intended for treatment of various forms of
diarrhea in dogs. Equilevia is Jaguar’s non-prescription
product for total gut health in equine athletes. Canalevia
and Equilevia contain ingredients isolated and purified from
the Croton lechleri tree, which is sustainably harvested. Neonorm
Calf and Neonorm Foal are Jaguar’s lead non-prescription
animal products. Mytesi®, Canalevia, Equilevia
and Neonorm are distinct products that act at the same last
step in a physiological pathway generally present in mammals.

For more information about Jaguar, please visit jaguar.health.
For more information about Napo, visit napopharma.com.

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking
statements.” These include statements regarding planned, potential
follow-on indications for Mytesi®. In some cases, you can
identify forward-looking statements by terms such as “may,” “will,”
“should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negative of these terms or other
similar expressions. The forward-looking statements in this release are
only predictions. Jaguar has based these forward-looking statements
largely on its current expectations and projections about future events.
These forward-looking statements speak only as of the date of this
release and are subject to a number of risks, uncertainties and
assumptions, some of which cannot be predicted or quantified and some of
which are beyond Jaguar’s control. Except as required by applicable law,
Jaguar does not plan to publicly update or revise any forward-looking
statements contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.

Jaguar-JAGX

Contacts

Jaguar Health, Inc.
Peter Hodge
phodge@jaguar.health